NEW YORK (GenomeWeb) – Veracyte today announced that it has entered into a definitive agreement to sell approximately $40 million in stock in a private placement.

Under the terms of the agreement, the investors will purchase 4,907,975 shares of common stock at $8.15 per share, the closing price on April 22, 2015. Investors include Broadfin Capital, Camber Capital, Deerfield, Longwood Capital Partners, and venBio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.